RSPI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RSPI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. RespireRx Pharmaceuticals's interest expense for the three months ended in Sep. 2023 was $ -0.07 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.44 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. RespireRx Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $ -0.33 Mil. RespireRx Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $ -0.07 Mil. RespireRx Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for RespireRx Pharmaceuticals's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RespireRx Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | -0.14 | -0.41 | -0.55 | -0.73 | -0.60 |
RespireRx Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Interest Expense | Get a 7-Day Free Trial | -0.10 | -0.07 | -0.07 | -0.23 | -0.07 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RespireRx Pharmaceuticals (OTCPK:RSPI) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
RespireRx Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $-0.07 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-0.33 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $0.00 Mil.
RespireRx Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as
RespireRx Pharmaceuticals did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
David Dickason | officer: SVP of Pre-Clinical Prod. Dev. | 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452 |
Timothy L. Jones | director, officer: CEO and President | 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452 |
Manuso James S J | director, officer: President & CEO | 5130 ROUTE 212, WILLOW NY 12495 |
Katie Macfarlane | director | 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540 |
Purcell Richard David Jr. | officer: SVP - Research & Deleopment | 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704 |
James Sapirstein | director | 1517 SAN JACINTO, HOUSTON TX 77002 |
Marc M Radin | officer: Controller | 33 FRANKLIN PLACE, GLEN ROCK NJ 07452 |
Robert N Weingarten | director, officer: Vice President and CFO | 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367 |
Aurora Capital Llc | other: Member of a 10% owner group | 354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167 |
Aurora Capital Corp | other: Member of 10% owner group | |
Jeff Eliot Margolis | director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group | C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016 |
Steven Chizzik | other: Member of 10% owner group | C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083 |
Arnold Lippa | director, officer: Chairman, CEO and President, other: Member of 10% owner group | C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016 |
T. Morgen Capital Llc | other: Member of 10% owner group | C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016 |
Kenneth M Cohen | other: Member of 10% owner group | 12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130 |
From GuruFocus
By Marketwired • 08-09-2023
By Stock market mentor Stock market mentor • 02-01-2023
By sperokesalga sperokesalga • 03-28-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 06-13-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By Value_Insider Value_Insider • 12-05-2022
By GuruFocusNews GuruFocusNews • 07-03-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 05-24-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.